万拉法新治疗强迫症对照研究

A Control Study On The Treatment Of Obsessive-compulsive Disorder With Venlafaxine

目的:比较万拉法新与氯米帕明治疗强迫症的疗效和不良反应。方法:对符合CCMD-3中国精神障碍分类与诊断标准患者60例,随机分组,分别给予万拉法新和氯米帕明治疗,疗程8周,用Yale-B rowm强迫症量表(Y-Bocs)、临床疗效总评量表、病情严重程度(CG I-SI)、副反应量表TESS分别在入组时和治疗8周后进行测定。结果:万拉法新与氯米帕明对于强迫症的治疗疗效相同,两组药物在治疗八周后临床疗效显著(P<0.01),其中万拉法新组显效率为80%,氯米帕明组显效率为79%,前者起效更快,不良反应少,依从性佳。结论:万拉法新是一种不良反应小、安全、有效的抗强迫症药物,在临床上可作为治疗强迫症推广药物。

Objective：To compare the efficacy and safety of venlafaxine and clomipramine in the treatment of obsessive compulsive. Methods：Sixty patients who met the diagnostic criteria of CCMD -3 were randomly divided into venlafaxine group and clomipramine group to treat for eight weeks . The efficacy and side effects were evaluated by Y - Bocs ,CGI - SI and TESS before treatment and after eight weeks. Results： Both drugs were similar in effect, and the efficacy was obvious after eight weeks （P 〈0.01 ）. The effective rate of venlafaxine group and clomipramine group were 80% and 79%, but venlafaxine took effect more quickly and its side effects were less and milder. Conclusions： Venlafaxine is an effective and safe antidepressant in the treatment of obsessive - compulsive disorder. It can be generally used in the treatment of obsessive - compulsive disorder.